ReviewExpert opinion on biological therapy2010
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.
Review in Expert opinion on biological therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 92 citations in OpenAlex.
- Clinical significance of coexisting Hashimoto's thyroiditis in differentiated thyroid cancer: a retrospective cohort study.BMC endocrine disorders · 2026Observational
- CXCR5Nature communications · 2026Article
- Acquisition and validation of four pain subtypes of colon adenocarcinoma and prognostic analysis.Journal of anesthesia and translational medicine · 2024Article
- Exploration of the causal relationship between inflammatory cytokines and prostate carcinoma: a comprehensive Mendelian randomization study.Frontiers in oncology · 2024Article
- Challenges in the Isolation and Proteomic Analysis of Cancer Exosomes-Implications for Translational Research.Proteomes · 2019Review
- Article
- Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model.International journal of cancer · 2018Article
- Modeling Macrophage Polarization and Its Effect on Cancer Treatment Success.Open journal of immunology · 2018Article
- Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma.Experimental and therapeutic medicine · 2017Article
- B cells inhibit the antitumor immunity against an established murine fibrosarcoma.Oncology letters · 2017Article
- Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways.International journal of molecular sciences · 2017Review
- Adenosine-mediated immunosuppression in patients with squamous cell carcinoma of the head and neck.HNO · 2016Review
- Cancer immunoprevention.Current opinion in immunology · 2016Review
- Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth.Biomaterials · 2016Article
- Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2015Article
- TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- Enhancing Cancer Immunotherapy Via Activation of Innate Immunity.Seminars in oncology · 2015Review
- Murine lung cancer induces generalized T-cell exhaustion.The Journal of surgical research · 2015Article
- Programmed death-1 checkpoint blockade in acute myeloid leukemia.Expert opinion on biological therapy · 2015Review
- The role of regulatory T cells in cancer immunology.ImmunoTargets and therapy · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
importance of the fieldImmunotherapy of cancer has not improved disease-free or overall patient survival. The lack of concordance between immunological and clinical responses in cancer immunotherapy trials is thought to result from the pervasive presence of tumor-driven immune suppression that allows tumor to escape and that has not been adequately targeted by current therapies. AREAS COVERED IN THIS REVIEW: Because multiple mechanisms of tumor induced suppression have been identified and shown to contribute to tumor escape, the opportunity arises to interfere with these mechanisms. A range of known tumor-derived inhibitors can now be blocked or neutralized by biologic or metabolic agents. Used alone or in combination with each other or with conventional cancer therapies, these agents offer novel therapeutic strategies for the control of tumor escape. WHAT THE READER WILL GAIN: This review deals with currently available inhibitors for counteracting tumor immune escape. The restoration of effective anti-tumor immunity in patients with cancer will require new approaches aiming at: i) protection of immune cells from adverse effects of myeloid-derived suppressor cells, regulatory T cells or inhibitory factors thus enhancing effector functions; and ii) prolonging survival of central memory T cells, thus ensuring long-term protection. TAKE HOME MESSAGE: Inhibitors of mechanisms responsible for tumor escape could restore anti-tumor immune responses in patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.